The role of prostaglandin E2 in human vascular inflammation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 2-3, 2013, Pages 55-63

  Gomez, I ^a,b   Foudi, N ^c   Longrois, D ^a,b,d   Norel, X ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c FERHAT ABBAS UNIVERSITY   (Algeria)

^d BICHAT HOSPITAL   (France)

Author keywords

Aneurysm; Angiogenesis; Artery; Atherosclerosis; Cancer; Cyclooxygenase; Inflammation; PGE2; Prostaglandin; Prostanoids; Vascular

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; VASCULOTROPIN; PROSTAGLANDIN;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; DRUG RECEPTOR BINDING; HUMAN; INTRACRANIAL ANEURYSM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE TONE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASCULITIS; ANEURYSM; IMMUNOLOGY; INFLAMMATION; METABOLISM; ARTERY; NEOPLASM; PGE(2); PROSTANOIDS; REVIEW; VASCULAR;

ANEURYSM; ATHEROSCLEROSIS; DINOPROSTONE; HUMANS; INFLAMMATION; VASCULAR DISEASES;

ANEURYSM; ANGIOGENESIS; ARTERY; ATHEROSCLEROSIS; CANCER; CYCLOOXYGENASE; INFLAMMATION; PGE(2); PROSTAGLANDIN; PROSTANOIDS; VASCULAR;

EID: 84880575923     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.04.004     Document Type: Article

References (155)

1. Bishop-Bailey D., Mitchell J.A., Warner T.D. COX-2 in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:956-958.
2. von Moltke J., Trinidad N.J., Moayeri M., et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 2012, 490:107-111.
3. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:986-1000.
4. Aoki T., Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol. Sci. 2012, 33:304-311.
5. Chen L., Yang G., Grosser T. Prostanoids and inflammatory pain. Prostaglandins Other Lipid Mediat. 2012.
6. Burke J.E., Dennis E.A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 50(Suppl.):S237-S242.
7. Astudillo A.M., Balgoma D., Balboa M.A., Balsinde J. Dynamics of arachidonic acid mobilization by inflammatory cells. Biochim. Biophys. Acta 2012, 1821:249-256.
8. Schaloske R.H., Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761:1246-1259.
9. Birts C.N., Barton C.H., Wilton D.C. Catalytic and non-catalytic functions of human IIA phospholipase A2. Trends Biochem. Sci. 2010, 35:28-35.
10. Cathcart M.K. Signal-activated phospholipase regulation of leukocyte chemotaxis. J. Lipid Res. 2009, 50(Suppl.):S231-S236.
11. Ahmed M.S., Ji J.Z., Meng Q.H. Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?. Inflamm. Allergy Drug Targets 2011, 10:236-246.
12. Gong H.P., Du Y.M., Zhong L.N., et al. Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis. 2011, 10:13.
13. Sarlon-Bartoli G., Boudes A., Buffat C., et al. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: A new biomarker for predicting unstable plaque. Eur. J. Vasc. Endovasc. Surg. 2012, 43:154-159.
14. Garavito R.M., Malkowski M.G., DeWitt D.L. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 2002, 68-69:129-152.
15. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. J. Lipid Res. 2009, 50(Suppl.):S423-S428.
16. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 2006, 119:229-240.
17. Bishop-Bailey D., Pepper J.R., Haddad E.B., Newton R., Larkin S.W., Mitchell J.A. Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1644-1648.
18. Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 1999, 155:1281-1291.
19. Foudi N., Louedec L., Cachina T., Brink C., Norel X. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovasc. Res. 2009, 81:269-277.
20. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 1999, 96:7220-7225.
21. Masuko-Hongo K., Berenbaum F., Humbert L., Salvat C., Goldring M.B., Thirion S. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum. 2004, 50:2829-2838.
22. Gutierrez-Venegas G., Jimenez-Estrada M., Maldonado S. The effect of flavonoids on transduction mechanisms in lipopolysaccharide-treated human gingival fibroblasts. Int. Immunopharmacol. 2007, 7:1199-1210.
23. Mbalaviele G., Pauley A.M., Shaffer A.F., et al. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem. Pharmacol. 2010, 79:1445-1454.
24. Payner T., Leaver H.A., Knapp B., et al. Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A. Mol. Cancer Ther. 2006, 5:1817-1826.
25. Camacho M., Gerboles E., Escudero J.R., Anton R., Garcia-Moll X., Vila L. Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E(2) biosynthesis in vascular smooth muscle cells. J. Thromb. Haemost. 2007, 5:1411-1419.
26. Soler M., Camacho M., Escudero J.R., Iniguez M.A., Vila L. Human vascular smooth muscle cells but not endothelial cells express prostaglandin E synthase. Circ. Res. 2000, 87:504-507.
27. Uracz W., Uracz D., Olszanecki R., Gryglewski R.J. Interleukin 1 beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells. J. Physiol. Pharmacol. 2002, 53:643-654.
28. Zuo W., Wu Z.H., Wu N., et al. Adiponectin receptor 1 mediates the difference in adiponectin-induced prostaglandin E2 production in rheumatoid arthritis and osteoarthritis synovial fibroblasts. Chin. Med. J. (Engl) 2011, 124:3919-3924.
29. Alcolea S., Anton R., Camacho M., et al. Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2. J. Lipid Res. 2012, 53:630-642.
30. Thoren S., Weinander R., Saha S., et al. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J. Biol. Chem. 2003, 278:22199-22209.
31. Flannagan R.S., Cosio G., Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat. Rev. Microbiol. 2009, 7:355-366.
32. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 2011, 12:21-27.
33. Camacho M., Lopez-Belmonte J., Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ. Res. 1998, 83:353-365.
34. Cheng L., Cao W., Fiocchi C., Behar J., Biancani P., Harnett K.M. Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G418-G428.
35. Gonzalez-Luis G., Perez-Vizcaino F., Blanco C.E., Villamor E. Age-related changes in isoprostane-mediated relaxation of piglet blood vessels. Front Biosci. (Elite Ed) 2010, 2:369-379.
36. Hausermann L., St-Louis J. Thromboxane and isoprostane share the same prostanoid receptors to increase human placental tone. Placenta 2011, 32:941-948.
37. Brochhausen C., Zehbe R., Watzer B., et al. Immobilization and controlled release of prostaglandin E2 from poly-L-lactide-co-glycolide microspheres. J. Biomed. Mater. Res. A 2009, 91:454-462.
38. Kozak K.R., Crews B.C., Ray J.L., Tai H.H., Morrow J.D., Marnett L.J. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J. Biol. Chem. 2001, 276:36993-36998.
39. Bygdeman M. Pharmacokinetics of prostaglandins. Best Pract. Res. Clin. Obstet. Gynaecol. 2003, 17:707-716.
40. Pham H., Chen M., Li A., et al. Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pancreas 2010, 39:332-339.
41. Ikeda-Matsuo Y., Ota A., Fukada T., Uematsu S., Akira S., Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc. Natl. Acad. Sci. USA 2006, 103:11790-11795.
42. Nakatani Y., Hokonohara Y., Kakuta S., Sudo K., Iwakura Y., Kudo I. Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal. Biochem. Biophys. Res. Commun. 2007, 362:387-392.
43. Lovgren A.K., Kovarova M., Koller B.H. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis. Mol. Cell Biol. 2007, 27:4416-4430.
44. Jania L.A., Chandrasekharan S., Backlund M.G., et al. Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis. Prostaglandins Other Lipid Mediat. 2009, 88:73-81.
45. Murakami M., Nakatani Y., Tanioka T., Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 2002, 68-69:383-399.
46. Murakami M., Nakashima K., Kamei D., et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem. 2003, 278:37937-37947.
47. Katoh H., Watabe A., Sugimoto Y., Ichikawa A., Negishi M. Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochim. Biophys. Acta 1995, 1244:41-48.
48. Woodward D.F., Jones R.L., Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 2011, 63:471-538.
49. An S., Yang J., So S.W., Zeng L., Goetzl E.J. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 1994, 33:14496-14502.
50. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal 2007, 7:1359-1374.
51. Foudi N., Gomez I., Benyahia C., Longrois D., Norel X. Prostaglandin E(2) receptor subtypes in human blood and vascular cells. Eur. J. Pharmacol. 2012, 695:1-6.
52. Kleiveland C.R., Kassem M., Lea T. Human mesenchymal stem cell proliferation is regulated by PGE2 through differential activation of cAMP-dependent protein kinase isoforms. Exp. Cell Res. 2008, 314:1831-1838.
53. Jiang H., Weyrich A.S., Zimmerman G.A., McIntyre T.M. Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility. J. Biol. Chem. 2004, 279:55905-55913.
54. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
55. Fritsch-Decker S., Both T., Mulhopt S., Paur H.R., Weiss C., Diabate S. Regulation of the arachidonic acid mobilization in macrophages by combustion-derived particles. Part. Fibre Toxicol. 2011, 8:23.
56. Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 2012, 188:21-28.
57. Foudi N., Kotelevets L., Gomez I., et al. Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2): implication for cardiovascular grafts. Br. J. Pharmacol. 2011, 163:826-834.
58. Vigano T., Habib A., Hernandez A., et al. Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells. Am. J. Respir. Crit. Care Med. 1997, 155:864-868.
59. Tammali R., Ramana K.V., Srivastava S.K. Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells. Cancer Lett. 2007, 252:299-306.
60. Jenab S., Quinones-Jenab V. The effects of interleukin-6, leukemia inhibitory factor and interferon-gamma on STAT DNA binding and c-fos mRNA levels in cortical astrocytes and C6 glioma cells. Neuro Endocrinol. Lett. 2002, 23:325-328.
61. Barrios-Rodiles M., Chadee K. Novel regulation of cyclooxygenase-2 expression and prostaglandin E2 production by IFN-gamma in human macrophages. J. Immunol. 1998, 161:2441-2448.
62. Abel K., La Franco-Scheuch L., Rourke T., et al. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. J. Virol. 2004, 78:841-854.
63. Gomez P.F., Pillinger M.H., Attur M., et al. Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J. Immunol. 2005, 175:6924-6930.
64. Minami M., Shimizu K., Okamoto Y., et al. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J. Biol. Chem. 2008, 283:9692-9703.
65. Shi J., Johansson J., Woodling N.S., Wang Q., Montine T.J., Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol. 2010, 184:7207-7218.
66. Jaulmes A., Thierry S., Janvier B., Raymondjean M., Marechal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. Faseb J. 2006, 20:1727-1729.
67. Biondi C., Fiorini S., Pavan B., Ferretti M.E., Barion P., Vesce F. Interactions between the nitric oxide and prostaglandin E2 biosynthetic pathways in human amnion-like WISH cells. J. Reprod. Immunol. 2003, 60:35-52.
68. Portanova J.P., Zhang Y., Anderson G.D., et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 1996, 184:883-891.
69. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 2006, 47:C13-C18.
70. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 2008, 54:24-38.
71. Arnett D.K., McClelland R.L., Bank A., et al. Biomarkers of inflammation and hemostasis associated with left ventricular mass: the Multiethnic Study of Atherosclerosis (MESA). Int. J. Mol. Epidemiol. Genet. 2011, 2:391-400.
72. Raval M., Frank P.G., Laury-Kleintop L., Yan G., Lanza-Jacoby S. Celecoxib combined with atorvastatin prevents progression of atherosclerosis. J. Surg. Res. 2010, 163:e113-e122.
73. Schober L.J., Khandoga A.L., Dwivedi S., et al. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood. J. Thromb. Thrombolysis 2011, 32:158-166.
74. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2054-2061.
75. Cipollone F. COX-2 and prostaglandins in atherosclerosis. Lupus 2005, 14:756-759.
76. Linton M.F., Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol. 2004, 4:116-123.
77. Trebino C.E., Stock J.L., Gibbons C.P., et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA 2003, 100:9044-9049.
78. Stichtenoth D.O., Thoren S., Bian H., Peters-Golden M., Jakobsson P.J., Crofford L.J. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J. Immunol. 2001, 167:469-474.
79. Cipollone F., Cicolini G., Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol. Ther. 2008, 118:161-180.
80. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021-2029.
81. Grosser T., Yu Y., Fitzgerald G.A. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med. 2010, 61:17-33.
82. Schror K., Bretschneider E., Fischer K., et al. Thrombin receptors in vascular smooth muscle cells-function and regulation by vasodilatory prostaglandins. Thromb. Haemost. 2010, 103:884-890.
83. Takayama K., Garcia-Cardena G., Sukhova G.K., Comander J., Gimbrone M.A., Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 2002, 277:44147-44154.
84. Grad E., Golomb M., Koroukhov N., et al. Aspirin reduces the prothrombotic activity of C-reactive protein. J. Thromb. Haemost. 2009, 7:1393-1400.
85. Hanriot D., Bello G., Ropars A., et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb. Haemost. 2008, 99:558-569.
86. Barish G.D., Evans R.M. PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol. Metab. 2004, 15:158-165.
87. Blaschke F., Leppanen O., Takata Y., et al. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ. Res. 2004, 95:e110-e123.
88. Crestani M., De Fabiani E., Caruso D., et al. LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem. Soc. Trans. 2004, 32:92-96.
89. Davies J.D., Carpenter K.L., Challis I.R., et al. Adipocytic differentiation and liver X receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. J. Biol. Chem. 2005, 280:3911-3919.
90. Li N., Rivera-Bermudez M.A., Zhang M., et al. LXR modulation blocks prostaglandin E2 production and matrix degradation in cartilage and alleviates pain in a rat osteoarthritis model. Proc. Natl. Acad. Sci. USA 2010, 107:3734-3739.
91. Cheng S., Afif H., Martel-Pelletier J., et al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J. Biol. Chem. 2004, 279:22057-22065.
92. Kapoor M., Kojima F., Yang L., Crofford L.J. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot. Essent. Fatty Acids 2007, 76:103-112.
93. Mendez M., LaPointe M.C. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003, 42:844-850.
94. Cipollone F., Prontera C., Pini B., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001, 104:921-927.
95. Sueyoshi S., Mitsumata M., Kusumi Y., et al. Increased expression of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma in human atherosclerosis. Pathol. Res. Pract. 2010, 206:429-438.
96. Iyu D., Juttner M., Glenn J.R., et al. PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 2011, 94:9-16.
97. Jones R.L., Wise H., Clark R., Whiting R.L., Bley K.R. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations. Br. J. Pharmacol. 2006, 149:110-120.
98. Philipose S., Konya V., Sreckovic I., et al. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2416-2423.
99. Fox S.C., May J.A., Johnson A., et al. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y(12) antagonist both in-vitro and ex-vivo in human volunteers. Platelets 2012.
100. Singh J., Zeller W., Zhou N., et al. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-d ichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J. Med. Chem. 2010, 53:18-36.
101. Yu Y., Ricciotti E., Scalia R., et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci. Transl. Med. 2012, 4:132ra54.
102. Cannon C.P., Cannon P.J. Physiology. COX-2 inhibitors and cardiovascular risk. Science 2012, 336:1386-1387.
103. Caughey G.E., Cleland L.G., Penglis P.S., Gamble J.R., James M.J. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J. Immunol. 2001, 167:2831-2838.
104. Pichiule P., Chavez J.C., LaManna J.C. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J. Biol. Chem. 2004, 279:12171-12180.
105. Kuriyama S., Kashiwagi H., Yuhki K., et al. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb. Haemost. 2010, 104:796-803.
106. Fowkes F.G., Anandan C.L., Lee A.J., et al. Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease. J. Vasc. Surg. 2006, 43:474-480.
107. Treska V., Topolcan O., Pecen L. Cytokines as plasma markers of abdominal aortic aneurysm. Clin. Chem. Lab. Med. 2000, 38:1161-1164.
108. Walton L.J., Franklin I.J., Bayston T., et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999, 100:48-54.
109. Miralles M., Wester W., Sicard G.A., Thompson R., Reilly J.M. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J. Vasc. Surg. 1999, 29:884-892. (discussion 92-3).
110. Dawson J., Cockerill G.W., Choke E., Belli A.M., Loftus I., Thompson M.M. Aortic aneurysms secrete interleukin-6 into the circulation. J. Vasc. Surg. 2007, 45:350-356.
111. Golledge J., Tsao P.S., Dalman R.L., Norman P.E. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008, 118:2382-2392.
112. Juncos L.I., Bunnell C.E., Alexander R.W., DeTure F.A. Renins and prostaglandins in segmental renal artery aneurysm associated with accelerated hypertension. Urology 1977, 9:321-326.
113. Hasan D.M., Mahaney K.B., Brown R.D., et al. Aspirin as a Promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011, 42:3156-3162.
114. Cheuk B.L., Cheng S.W. Can local secretion of prostaglandin E2, thromboxane B2, and interleukin-6 play a role in ruptured abdominal aortic aneurysm?. World J. Surg. 2008, 32:55-61.
115. Cheuk B.L., Cheng S.W. Differential secretion of prostaglandin E(2), thromboxane A(2) and interleukin-6 in intact and ruptured abdominal aortic aneurysms. Int. J. Mol. Med. 2007, 20:391-395.
116. Holmes D.R., Wester W., Thompson R.W., Reilly J.M. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J. Vasc. Surg. 1997, 25:810-815.
117. Wang M., Lee E., Song W., et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 2008, 117:1302-1309.
118. Bayston T., Ramessur S., Reise J., Jones K.G., Powell J.T. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J. Vasc. Surg. 2003, 38:354-359.
119. Rong J.X., Shapiro M., Trogan E., Fisher E.A. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc. Natl. Acad. Sci. USA 2003, 100:13531-13536.
120. Han Y., Mao F., Wu Y., et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int. J. Biol. Markers 2011, 26:209-215.
121. Chen E.P., Smyth E.M. COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat. 2011, 96:14-20.
122. Il'yasova D., Colbert L.H., Harris T.B., et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2413-2418.
123. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence. Histopathology 2011, 60:199-215.
124. Malerba M., Montuschi P. Non-invasive biomarkers of lung inflammation in smoking subjects. Curr. Med. Chem. 2012, 19:187-196.
125. Salvado M.D., Alfranca A., Haeggstrom J.Z., Redondo J.M. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol. Med. 2012, 18:233-243.
126. Wang D., Dubois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
127. Backlund M.G., Mann J.R., Holla V.R., et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 2005, 280:3217-3223.
128. Thiel A., Ganesan A., Mrena J., et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin. Cancer Res. 2009, 15:4572-4580.
129. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
130. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 2003, 278:35451-35457.
131. Wang D., Wang H., Brown J., et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 2006, 203:941-951.
132. Jain S., Chakraborty G., Raja R., Kale S., Kundu G.C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res. 2008, 68:7750-7759.
133. Buchanan F.G., Gorden D.L., Matta P., Shi Q., Matrisian L.M., DuBois R.N. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl. Acad. Sci. USA 2006, 103:1492-1497.
134. Gentile L.B., Piva B., Diaz B.L. Hypertonic stress induces VEGF production in human colon cancer cell line Caco-2: inhibitory role of autocrine PGE. PLoS One 2011, 6:e25193.
135. Ding Y.B., Shi R.H., Tong J.D., et al. PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp. Oncol. 2005, 27:108-113.
136. Li W., Liu M.L., Cai J.H., Tang Y.X., Zhai L.Y., Zhang J. Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo. Oncol. Lett. 2012, 4:168-174.
137. Bankhurst A.D. The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol. 1982, 7:85-91.
138. Walker W., Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004, 111:298-305.
139. Aronoff D.M., Canetti C., Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 2004, 173:559-565.
140. Serezani C.H., Chung J., Ballinger M.N., Moore B.B., Aronoff D.M., Peters-Golden M. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol. 2007, 37:562-570.
141. Camitta M.G., Gabel S.A., Chulada P., et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001, 104:2453-2458.
142. Markosyan N., Chen E.P., Ndong V.N., et al. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 2011, 32:1441-1449.
143. Samuelsson B., Morgenstern R., Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007, 59:207-224.
144. Wang M., Zukas A.M., Hui Y., Ricciotti E., Pure E., FitzGerald G.A. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA 2006, 103:14507-14512.
145. Jia Z., Wang H., Yang T. Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction. Hypertension 2012, 59:122-128.
146. Schroder O., Yudina Y., Sabirsh A., Zahn N., Haeggstrom J.Z., Stein J. 15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells. J. Lipid Res. 2006, 47:1071-1080.
147. Zhang J., Fujii S., Wu Z., et al. Involvement of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced prostaglandin E2 production by microglia. J. Neuroimmunol. 2006, 172:112-120.
148. Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 2000, 275:32775-32782.
149. Miyaki A., Yang P., Tai H.H., Subbaramaiah K., Dannenberg A.J. Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G559-G566.
150. Colombe L., Michelet J.F., Bernard B.A. Prostanoid receptors in anagen human hair follicles. Exp. Dermatol. 2008, 17:63-72.
151. White K.E., Ding Q., Moore B.B., et al. Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J. Immunol. 2008, 180:637-646.
152. Tang E.H., Jensen B.L., Skott O., et al. The role of prostaglandin E and thromboxane-prostanoid receptors in the response to prostaglandin E2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rats. Cardiovasc. Res. 2008, 78:130-138.
153. Scott G., Leopardi S., Printup S., Malhi N., Seiberg M., Lapoint R. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J. Invest. Dermatol. 2004, 122:1214-1224.
154. White E.S., Atrasz R.G., Dickie E.G., et al. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am. J. Respir. Cell. Mol. Biol. 2005, 32:135-141.
155. Fujino H., Salvi S., Regan J.W. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 2005, 68:251-259.